PMC:3940921 / 27307-28603 JSONTXT

{"project":"2_test","denotations":[{"id":"24590311-10910924-79065561","span":{"begin":680,"end":681},"obj":"10910924"},{"id":"24590311-20417730-79065562","span":{"begin":756,"end":758},"obj":"20417730"}],"text":"Cells and culture conditions\nA number of cell lines were used to reflect a spectrum of imatinib-sensitive and -resistant disease. Ba/F3 cells transfected with p210 and mutated (T315I, M351T, H396P) BCR-ABL were kindly provided by Dr. Brian Druker, (Oregon Health and Science University, Portland, OR, USA). K562 cells were purchased from the European Collection of Cell Cultures (Salisbury, UK). LAMA84 imatinib-sensitive and -resistant clones (LAMA84S and LAMA84R) and KCL22 imatinib-sensitive and -resistant clones (KCL22S and KCL22R) were provided by Professor Junia Melo. LAMA84R cells have increased copy numbers of BCR-ABL and express the multidrug resistance p-glycoprotein4 and the mechanism of resistance in KCL22R cells is independent of BCR-ABL.41 Cells were cultured in a humidified incubator at 37 °C and 5% CO2 in RPMI-1640 supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal calf serum (Gibco BRL, Paisley, UK). LAMA84R and KCL22R cell lines were cultured continuously in the presence of 1 μM imatinib. A549 lung carcinoma cells (European Collection of Cell Cultures) were cultured in DMEM supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal calf serum. Authentication was conducted by LGC Standards Cell Line Authentication Service."}